EcoDrugPlus

Chemokine (C-X-C Motif), Receptor 4b

Ensembl ID : ENSORLG00000029079
Gene Symbol: CXCR4B
4 Cross references
201 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSORLG00000006989
Gene Symbol: CCKAR
4 Cross references
200 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSORLG00000024681
Gene Symbol: CCKBRA
4 Cross references
193 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSORLG00000017966
Gene Symbol: LOC101161683
3 Cross references
191 Possible Orthologues:

Cholesterol 24-Hydroxylase

Ensembl ID : ENSORLG00000010534
Gene Symbol: LOC101165274
3 Cross references
256 Possible Orthologues:

Cholesterol 24-Hydroxylase

Ensembl ID : ENSORLG00000010516
Gene Symbol: LOC101165021
3 Cross references
256 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSORLG00000000375
Gene Symbol: CETP
4 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSORLG00000005239
Gene Symbol: CHRM3
4 Cross references
187 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSORLG00000013118
Gene Symbol: CHRNA3
4 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSORLG00000009700
Gene Symbol: CHRNB2
4 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSORLG00000013114
Gene Symbol: CHRNB4
4 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSORLG00000030214
Gene Symbol: CHRM2A
4 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).